Cardio-oncology: need for novel structures
- 180 Downloads
Cancer and cardiovascular diseases are the main causes for morbidity and mortality in modern society. In the United States of America (USA), over 1.7 million new cancer cases will presumably be observed in 2018. Progress in cancer treatment has greatly improved survival and it is estimated that 15.5 million cancer survivors currently live in the USA. The number of cancer survivors is expected to increase by 68% until 2040. Moreover, the portion of cancer survivors at the age of 65 years or older will increase from 62% to approximately 73% in 2040 which in turn enhances comorbidities in cancer survivors. Increased survival and age of cancer patients has unmasked the burden of cancer and cancer therapy-associated cardiovascular diseases. Depending on cancer treatment modalities, early cardiovascular toxicity is observed in up to 48% of patients. Late cardiotoxicity can be found in 30% of patients at 13 years after cancer treatment. Cardio-oncology aims to identify cancer therapy-related cardiovascular side effects and to provide optimum multidisciplinary care for cancer patients. So far, scientific effort has generated a profound knowledge on underlying pathomechanisms and clinical implications but standardized recommendations and structural requirements for cardio-oncology care are still limited.
KeywordsAnthracyclines Cancer Cardio-oncology Cardiotoxicity
immune checkpoint inhibitor
magnetic resonance imaging
Cancer and cardiovascular diseases are the main causes for morbidity and mortality in modern society . In the United States of America (USA), over 1.7 million new cancer cases will presumably be observed in 2018 . Progress in cancer treatment has greatly improved survival and it is estimated that 15.5 million cancer survivors currently live in the USA. The number of cancer survivors is expected to increase by 68% until 2040 . Moreover, the portion of cancer survivors at the age of 65 years or older will increase from 62% to approximately 73% in 2040 which in turn enhances comorbidities in cancer survivors . Increased survival and age of cancer patients has unmasked the burden of cancer and cancer therapy-associated cardiovascular diseases . Depending on cancer treatment modalities, early cardiovascular toxicity is observed in up to 48% of patients. Late cardiotoxicity can be found in 30% of patients at 13 years after cancer treatment [4, 5]. Cardio-oncology aims to identify cancer therapy-related cardiovascular side effects and to provide optimum multidisciplinary care for cancer patients [4, 6]. So far, scientific effort has generated a profound knowledge on underlying pathomechanisms and clinical implications but standardized recommendations and structural requirements for cardio-oncology care are still limited.
Anthracyclines have been identified as the prototype for cardiotoxicity in cancer therapy. This group of substances (e.g. doxorubicin, daunorubicin, epirubicin) is used in a variety of malignancies, e.g. breast cancer and hematologic cancers. Anthracyclines induce left ventricular (LV) dysfunction in 18–48% of patients . The generation of reactive oxygen species and inhibition of topoisomerase II has been identified as the underlying pathomechanism of anthracycline-induced cardiotoxicity . Several groups of patients receiving cancer therapy are at increased risk for development of cancer therapy-related cardiotoxicity. Particularly, cardiovascular risk of survivors of childhood cancer is highly elevated . In pediatric patients treated with anthracyclines and radiotherapy, the overall risk for cardiac disease was 62-fold increased . The median onset of cardiac disease was at the age of 29 years with a cumulative incidence of first diagnosis of cardiac disease of 11% at the age of 40 . Despite these alarming data considering the young age of this group of patients, insufficient scientific effort has been undertaken so far to investigate potential cardioprotective measures and to implement standardized long-term cardio-oncologic monitoring of this collective into clinical routine . Elderly patients with cardiovascular comorbidities represent a second group that is highly relevant for cardiotoxic side effects that is continuously growing with increasing age of cancer survivors [3, 4]. Here, presence of arterial hypertension, diabetes mellitus, smoking, anthracyclines and manifest coronary artery disease augment the risk for cardiotoxicity [4, 5, 9]. Lipid monitoring and management of modifiable risk factors is beneficial in the prevention of cancer therapy-induced cardiotoxicity . However, a standardized approach (e.g. target serum lipid values) has not yet been established for cancer patients.
Within the last decade, targeted tumor therapy has partly replaced or complemented conventional chemotherapy. While at first no effect on the cardiovascular system was suspected, large-scale application of several targeted substances has revealed various significant cardiovascular adverse effects . Anti-vascular endothelial growth factor receptor therapy increases the risk of cardiac ischemia and hypertension [11, 12]. Tyrosine kinase inhibitors have been successfully implemented in the treatment of metastatic melanoma but were shown to induce hypertension and LV dysfunction . Patients treated with immune checkpoint inhibitors (ICI) are prone to autoimmune-triggered adverse events such as fulminant lymphocytic myocarditis in 1.14% [7, 14]. Considering these severe side effects of various new therapies that are increasingly implemented in cancer therapy, cardiotoxicity of novel therapeutics will be of particular importance for the management of future cancer patients.
At our institution, a cardio-oncology unit has been established as an in-hospital service and as an outpatient clinic. For the assessment of various forms of cardiotoxic effects, diagnostic pathways were created aiming to provide a standardized treatment of patients receiving conventional chemotherapy or different forms of targeted therapies. Baseline diagnostics including cardiac biomarkers and echocardiography with strain analysis, magnetic resonance imaging (MRI) and positron emission tomography–MRI are available for an individualized diagnostic assessment. The establishment of efficient cooperations and workflows within the involved departments appeared to be the most critical factor for the best possible cardio-oncology service.
The increasing demand for cardio-oncology care has led to the establishment of working groups within the European and German Society of Cardiology. However, a standardized advanced training and accreditation system for cardiologists working in the field of cardio-oncology is necessary to maintain high quality of cardio-oncology care . Taken together, the implementation of cardio-oncology has greatly improved treatment of cardiovascular adverse events in cancer patients. Standardization of monitoring and treatment processes is now urgently needed to ensure optimum treatment quality.
LM and TR carried out the literature search and drafted the manuscript. Both authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
Consent for publication
Ethics approval and consent to participate
Lars Michel acknowledges the following funding source: IFORES research grant from the Medical Faculty, University Duisburg-Essen, Germany.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 2.Institute NC. Annual report to the nation on the status of cancer. In: Surveillance, epidemiology, and end results program. 2018. https://seer.cancer.gov/statfacts/.
- 4.Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801.CrossRefGoogle Scholar
- 12.Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.